Roche's Tecentriq notches third cancer cocktail trial win

ZURICH (Reuters) – Roche’s immunotherapy Tecentriq on Tuesday racked up a third trial win in combination with other cancer drugs, a boost for the Swiss drugmaker as it seeks to muscle in on space dominated by Merck and Bristol-Myers Squibb.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *